Metropolis Healthcare has reported its audited financial results for the quarter and year ended March 31, 2026. The company announced a 2nd interim dividend of ₹1 per equity share and confirmed a transition in its senior leadership, with Dr. Nilesh Shah moving to an advisory role. Additionally, the Board has recommended the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as the company’s new statutory auditors for a five-year term.
Strong Financial Performance
For the quarter ended March 31, 2026, Metropolis Healthcare recorded revenue from operations of ₹35,203.12 lakhs on a standalone basis, with total standalone profit for the year reaching ₹15,748.33 lakhs. On a consolidated basis, the company demonstrated robust growth, with annual consolidated revenue from operations rising to ₹164,584.59 lakhs and a total consolidated profit of ₹19,118.20 lakhs for the year.
Dividend and Governance Updates
The Board of Directors has declared a 2nd interim dividend of ₹1 per equity share (face value of ₹2). The record date for this payout is set for Tuesday, May 19, 2026. Furthermore, the company is set to appoint Deloitte Haskins & Sells Chartered Accountants LLP as its new statutory auditors for a five-year term, covering the period from the conclusion of the 26th Annual General Meeting through to the 31st Annual General Meeting, replacing the retiring firm, B S R & Co. LLP.
Leadership Transition
In a move to strengthen its strategic advisory capabilities, Dr. Nilesh Shah will transition from his full-time role as President – Internal Assurance to an advisory capacity effective May 14, 2026. This change marks a significant shift in the senior management structure as the company continues to evolve its internal oversight and assurance functions.
Source: BSE
